Organogenesis Holdings Stock Today
| ORGO Stock | USD 2.97 0.07 2.41% |
Performance0 of 100
| Odds Of DistressLess than 3
|
Organogenesis Holdings is selling at 2.97 as of the 23rd of April 2024; that is 2.41 percent increase since the beginning of the trading day. The stock's open price was 2.9. Organogenesis Holdings has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Organogenesis Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of January 2024 and ending today, the 23rd of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of January 2017 | Category Healthcare | Classification Health Care |
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company was founded in 1985 and is headquartered in Canton, Massachusetts. The company has 131.96 M outstanding shares of which 7.23 M shares are now shorted by private and institutional investors with about 9.31 trading days to cover. More on Organogenesis Holdings
Moving against Organogenesis Stock
| 0.89 | ANIP | ANI Pharmaceuticals Financial Report 13th of May 2024 | PairCorr |
| 0.78 | SUPN | Supernus Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
| 0.77 | AVTE | Aerovate Therapeutics Financial Report 20th of May 2024 | PairCorr |
| 0.76 | OPT | Opthea | PairCorr |
| 0.67 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
| 0.66 | CNTA | Centessa Pharmaceuticals Downward Rally | PairCorr |
| 0.63 | PAHC | Phibro Animal Health Financial Report 1st of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 8th of May 2024
Organogenesis Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Organogenesis Holdings' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Organogenesis Holdings or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO, President | Gary Sr | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Organogenesis Holdings report their recommendations after researching Organogenesis Holdings' financial statements, talking to executives and customers, or listening in on Organogenesis Holdings' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Organogenesis Holdings. The Organogenesis consensus assessment is calculated by taking the average forecast from all of the analysts covering Organogenesis Holdings. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Organogenesis Holdings' liquidity, profitability, solvency, and operating efficiency, Organogenesis Holdings is doing better financially then in previous quarter. It has a moderate odds of reporting better financial numbers in May. Financial strength of Organogenesis Holdings is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organogenesis Holdings' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Organogenesis Holdings' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Organogenesis Holdings' financial leverage. It provides some insight into what part of Organogenesis Holdings' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organogenesis Holdings (ORGO) is traded on NASDAQ Exchange in USA. It is located in 85 Dan Road, Canton, MA, United States, 02021 and employs 862 people. Organogenesis Holdings is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 391.93 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Organogenesis Holdings's market, we take the total number of its shares issued and multiply it by Organogenesis Holdings's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Organogenesis Holdings conducts business under Biotechnology sector and is part of Health Care industry. The entity has 131.96 M outstanding shares of which 7.23 M shares are now shorted by private and institutional investors with about 9.31 trading days to cover.
Organogenesis Holdings currently holds about 113.24 M in cash with 30.92 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87.
Check Organogenesis Holdings Probability Of Bankruptcy
Ownership AllocationOrganogenesis Holdings has a total of 131.96 Million outstanding shares. Organogenesis Holdings has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Organogenesis Ownership Details
Organogenesis Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Organogenesis Holdings jumping above the current price in 90 days from now is about 69.15%. The Organogenesis Holdings probability density function shows the probability of Organogenesis Holdings stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.7117. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Organogenesis Holdings will likely underperform. Additionally, organogenesis Holdings has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Organogenesis Holdings to move above the current price in 90 days from now is about 69.15 (This Organogenesis Holdings probability density function shows the probability of Organogenesis Stock to fall within a particular range of prices over 90 days) .
Organogenesis Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Organogenesis Holdings that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Organogenesis Holdings' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Organogenesis Holdings' value.| Instituion | Recorded On | Shares | |
| Assenagon Asset Management Sa | 2023-12-31 | 971.7 K | |
| Millennium Management Llc | 2023-12-31 | 946.2 K | |
| Two Sigma Advisers, Llc | 2023-12-31 | 877.9 K | |
| Renaissance Technologies Corp | 2023-12-31 | 857.7 K | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 834 K | |
| Marshall Wace Asset Management Ltd | 2023-12-31 | 822.2 K | |
| Northern Trust Corp | 2023-12-31 | 625.9 K | |
| Citadel Advisors Llc | 2023-09-30 | 618.8 K | |
| Two Sigma Investments Llc | 2023-12-31 | 557.1 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 13.4 M | |
| Soleus Capital Management, L.p. | 2023-12-31 | 9 M |
Organogenesis Holdings Historical Income Statement
Organogenesis Holdings Income Statement is one of the three primary financial statements used for reporting Organogenesis's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Organogenesis Holdings revenue and expense. Organogenesis Holdings Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Organogenesis Holdings' Net Income is very stable compared to the past year. As of the 23rd of April 2024, Income Tax Expense is likely to grow to about 5.7 M, while Interest Expense is likely to drop about 2.1 M. View More FundamentalsOrganogenesis Stock Against Markets
Picking the right benchmark for Organogenesis Holdings stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Organogenesis Holdings stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Organogenesis Holdings is critical whether you are bullish or bearish towards Organogenesis Holdings at a given time. Please also check how Organogenesis Holdings' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Organogenesis Holdings without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Comparator Now
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account |
| All Next | Launch Module |
Organogenesis Holdings Corporate Management
Elected by the shareholders, the Organogenesis Holdings' board of directors comprises two types of representatives: Organogenesis Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Organogenesis. The board's role is to monitor Organogenesis Holdings' management team and ensure that shareholders' interests are well served. Organogenesis Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Organogenesis Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA Esq | VP Counsel | Profile | |
| Patrick Bilbo | Chief Officer | Profile | |
| Thomas Pearl | Vice Resources | Profile | |
| Zorina Pitkin | VP Systems | Profile | |
| Brian Grow | Chief Officer | Profile | |
| Kurt Matheson | VP Marketing | Profile |
How to buy Organogenesis Stock?
Before investing in Organogenesis Holdings, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Organogenesis Holdings. To buy Organogenesis Holdings stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Organogenesis Holdings. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Organogenesis Holdings stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Organogenesis Holdings stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Organogenesis Holdings stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Organogenesis Holdings, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Organogenesis Stock please use our How to Invest in Organogenesis Holdings guide.
Already Invested in Organogenesis Holdings?
The danger of trading Organogenesis Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Organogenesis Holdings is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Organogenesis Holdings. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Organogenesis Holdings is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Organogenesis Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organogenesis Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organogenesis Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organogenesis Holdings Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.Note that the Organogenesis Holdings information on this page should be used as a complementary analysis to other Organogenesis Holdings' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Organogenesis Stock analysis
When running Organogenesis Holdings' price analysis, check to measure Organogenesis Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Organogenesis Holdings is operating at the current time. Most of Organogenesis Holdings' value examination focuses on studying past and present price action to predict the probability of Organogenesis Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Organogenesis Holdings' price. Additionally, you may evaluate how the addition of Organogenesis Holdings to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Organogenesis Holdings' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 11.307 | Earnings Share 0.04 | Revenue Per Share 3.301 | Quarterly Revenue Growth (0.14) | Return On Assets 0.0224 |
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.